AstraZeneca
This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
Hepatocellular Carcinoma
Durvalumab
Tremelimumab
Phase 3
Study Type : | Interventional |
Estimated Enrollment : | 210 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma |
Actual Study Start Date : | February 22, 2023 |
Estimated Primary Completion Date : | March 31, 2025 |
Estimated Study Completion Date : | March 31, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: cohort 1 durvalumab in combination with tremelimumab |
Drug: Durvalumab Drug: Tremelimumab |
Experimental: cohort 2 durvalumab in combination with tremelimumab |
Drug: Durvalumab Drug: Tremelimumab |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Research Site
Beijing, China, 100021
Active, not recruiting
Research Site
Beijing, China, 100142
Recruiting
Research Site
Beijing, China, 211405
Recruiting
Research Site
Beijing, China, CN-100730
Completed
Research Site
Changsha, China, 410005
Recruiting
Research Site
Changsha, China, 410013
Active, not recruiting
Research Site
Chengdu, China, 610041
Recruiting
Research Site
Fuzhou, China, 350011
Recruiting
Research Site
Guangzhou, China, 510060
Active, not recruiting
Research Site
Guangzhou, China, 510100
Recruiting
Research Site
Guangzhou, China, 510260
Recruiting
Research Site
Guangzhou, China, 510515
Recruiting
Research Site
Hangzhou, China, 310022
Recruiting
Research Site
Harbin, China, 150081
Recruiting
Research Site
Ji Nan, China, 2501117
Recruiting
Research Site
Nanjing, China, 2100008
Recruiting
Research Site
Nanjing, China, 210009
Recruiting
Research Site
Nanjing, China, 210029
Recruiting
Research Site
Ningbo, China, 315010
Recruiting
Research Site
Shanghai, China, 200032
Active, not recruiting
Research Site
Shanghai, China, 200040
Active, not recruiting
Research Site
Shenyang, China, 110001
Active, not recruiting
Research Site
Tianjin, China, 300000
Withdrawn
Research Site
Tianjin, China, 300060
Withdrawn
Research Site
Tianjin, China, 300170
Recruiting
Research Site
Wenzhou, China, 325000
Recruiting
Research Site
Wuhan, China, 430022
Recruiting
Research Site
Wuhan, China, 430079
Recruiting
Research Site
Xi'an, China, 710038
Active, not recruiting
Research Site
Zhangjiagang, China, 215699
Withdrawn
Research Site
Zhengzhou, China, 450000
Active, not recruiting
Research Site
Zhengzhou, China, 450008